Oral News and Research

RSS

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

WHO, UNICEF issue guide, call for more research into medicines for children

Along with the release of a WHO-UNICEF guide on medicines for children, the U.N. agencies on Friday said the guide "exposed dangerous shortfalls" in medicines designed for children and called for more research into treating children, Reuters reports. "While effective medicines exist to fight disease and treat life-threatening conditions like malnutrition, formulations suitable for children are often difficult to source," Francisco Blanco, UNICEF's chief of medicines and nutrition, said, according to the news service.

3 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.

3 May 2010

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer.

3 May 2010

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.

3 May 2010

Smoking can increase risk of second cancer in breast cancer survivors

Women who survive early-stage breast cancer and smoke have an increased chance of developing a new second cancer in their other breast or elsewhere.

3 May 2010

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010

Boston Scientific to present multiple clinical abstracts on its endoscopy products at DDW 2010

Boston Scientific Corporation today announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its SpyGlass Direct Visualization System, Radial Jaw 4 Biopsy Forceps and WallFlex Duodenal Stent will be presented at Digestive Disease Week, May 1 – 5 in New Orleans.

30 Apr 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the first quarter of 2010.

30 Apr 2010

UNICEF, WHO release new publication on medicines formulated for children

A new publication that lists medicines formulated for children is being made available online by UNICEF and the World Health Organization, to help doctors and organizations obtain some of the 240 essential medicines that can save the lives of children.

30 Apr 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received a new patent in the United States.

30 Apr 2010

Women with family history of breast cancer face increase risk of ovarian cancer

Ovarian cancer is the most deadly disease of the female reproductive system, with most cases diagnosed in later stages. Yet while ovarian cancer affects 1 in 70 women in the United States, many women have never discussed the risk with their doctor.

30 Apr 2010

Gonorrhea may soon become untreatable according to WHO

According to the World Health organization (WHO), gonorrhea may soon become untreatable and urgent measures need to be taken to prevent and treat the sexually transmitted infection. This is the result of improper use of first line antibiotics which has led to widespread anti microbial resistance to drugs. The cheaper antibiotics no longer have as much effect as they should and the higher antibiotics will soon lose efficacy as well.

30 Apr 2010

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

29 Apr 2010

Oral News and Research

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

WHO, UNICEF issue guide, call for more research into medicines for children

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

Smoking can increase risk of second cancer in breast cancer survivors

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Boston Scientific to present multiple clinical abstracts on its endoscopy products at DDW 2010

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

UNICEF, WHO release new publication on medicines formulated for children

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Women with family history of breast cancer face increase risk of ovarian cancer

Gonorrhea may soon become untreatable according to WHO

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News